Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: A retrospective analysis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  van der Geest, Patrick J ^a   Dieters, Erik I ^a   Rijnders, Bart ^a   Groeneveld, Johan A B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amphotericin B; Efficacy; Lung injury; Mechanical ventilation; Pneumonia; Safety

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B; AMPHOTERICIN B, DEOXYCHOLATE DRUG COMBINATION; DEOXYCHOLIC ACID; DRUG COMBINATION;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CANDIDA; CANDIDIASIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNGAL COLONIZATION; FUNGUS CULTURE; HUMAN; INTENSIVE CARE UNIT; INTENSIVIST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; NEBULIZER; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; UNIVERSITY HOSPITAL; VENTILATOR ASSOCIATED PNEUMONIA; AGED; CRITICAL ILLNESS; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATORY TRACT INFECTIONS;

ADMINISTRATION, INHALATION; ADULT; AGED; AMPHOTERICIN B; CANDIDA; CANDIDIASIS; CRITICAL ILLNESS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84990047386     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0575-3     Document Type: Article

References (25)

1. El-Ebiary M, Torres A, Fabregas N, Puig de la Bellacasan J, Gonzalez J, Ramirez J, del Bano D, Hernandez C, Jimenez de Anta MT: Significance of the isolation of candida species from the respiratory samples in critically ill, non-neutropenic patients: an immediate post-mortem histologic study. Am J Respir Crit Care Med 1997, 156:583-590.
2. Rello J, Esandi ME, Diaz E, Mariscal D, Gallego M, Valles J: The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998, 14:146-149.
3. Charles PE, Dalle F, Doise JM, Quenot JP, Aho LS, Chavanet P, Blettery B: Candida spp. colonization significance in critically ill medical patients; a prospective study. Intensive Care Med 2005, 31:393-400.
4. Eggimann P, Calandra T, Fluckiger U, Bille J, Garbino J, Glauser MP, Marchetti O, Ruef C, Tauber M, Pittet D: Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Med 2005, 31:1514-1521.
5. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, Leon MA: A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737.
6. Delisle M-S, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK: The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 2008, 23:11-17.
7. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaarden E: Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009, 35:1526-1531.
8. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ: ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbial Infect 2012, 18:19-37.
9. Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B: Candida colonization of the respiratory tract and subsequent Pseudomonas ventilator-associated pneumonia. Chest 2006, 129:110-117.
10. Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, Quenot JP, Charles PE: Candida spp. airway colonization could promote antibiotic resistant bacteria selection in patients with suspected ventilator associated pneumonia. Intensive Care Med 2012, l38:1272-1279.
11. Nseir S, Jozefowicz E, Cavestri B, Senid B, Di Pompeo C, Dewayrin F, Favory R, Roussel-Delvallez M, Durocher A: Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med 2007, 33:137-142.
12. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Lowenberg B, Vulto A, Lugtenburg PJ, de Marie S: Aerolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized placebo controlled trial. Clin Infect Dis 2008, 46:1401-1408.
13. Kuiper L, Ruijgrok EJ: A review on the clinical use of inhaled amphotericin B. J Aerosol Med Pulm Drug Del 2009, 22:213-227.
14. De Jonge E, Schultz MJ, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, Kesecioglu J: Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. The Lancet 2003, 362:1011-1016.
15. De Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJ, Bernards AT, Kuijper EJ, Joore JC, Leverstein-van Hall MA, Bindels AJ, Jansz AR, Wesselink RM, de Jongh BM, Dennesen PJ, van Asselt GJ, te Velde LF, Frenay IH, Kaasjager K, Bosch FH, van Iterson M, Thijsen SF, Kluge GH, Pauw W, de Vries JW, Kaan JA, et al: Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009, 360:20-31.
16. Ong DS, Klein Klouwenberg P, Spitoni C, Bonten MJ, Cremer OL: Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: a cohort study. Crit Care 2013, 17:R233.
17. Van t' Veen A, Gommers D, Mouton JW, Kluytmans JA, Krijt EJ, Lachmann B: Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. Br J Pharmacol 1996, 118:593-598.
18. Ruijgrok EJ, Vulto AG, Van Etten WM: Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromized rats. J Antimicrob Chemother 2001, 48:89-95.
19. Knechtel SA, Klepser ME: Safety of aerolized amphotericin B. Expert Opin Drug Saf 2007, 6:523-532.
20. Fauvel M, Farrugia C, Tsapis N, Gueuti C, Cabaret O, Bories C, Bretagne S, Barratt G: Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity. Int J Pharm 2012, 436:106-110.
21. Monforte V, López-Sánchez A, Zurbano F, Usseti P, Sole A, Casals C, Cifrian J, de Pablos A, Bravo C, Roman A: Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J Heart Lung Transplant 2013, 32:313-319.
22. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE: Diagnosis of ventilatorassociated pneumonia: controversies and working toward a gold standard. Curr Opin Infect Dis 2013, 26:140-150.
23. Rosbolt MB, Sterling ES, Fahy BG: The utility of the clinical pulmonary infection score. J Intensive Care Med 2009, 24:26-34.
24. Murray JF, Matthay MA, Luce JM, Flick MR: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138:720-723.
25. Hamil RJ: Amphotericin B, formulations: a comparison review of efficacy and toxicity. Drugs 2013, 73:919-934.